Efficacy of SNX-1012 in the Treatment of Oral Mucositis

Study Overview
=================
Brief Summary
-----------------
Oral mucositis (OM) is a common and debilitating toxicity induced by many chemotherapy (CT) regimens and by radiation to the head and neck. The purpose of this study is to determine the effectiveness of SNX-1012 in decreasing the duration of Grade 2, 3, or 4 oral mucositis (OM) according to World Health Organization (WHO) criteria.

Official Title
-----------------
A Phase 2, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Efficacy of SNX-1012 in Reducing the Duration and Severity of Ulcerative Oral Mucositis in Patients Receiving Cytotoxic Chemotherapy for Breast or Lung Cancer

Conditions
-----------------
Stomatitis, Oral Mucositis

Intervention / Treatment
-----------------
* Drug: SNX-1012 (meclocycline sulfosalicylate)
* Drug: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Signed written informed consent Naive to focal radiation therapy in the head and neck regions for cancer prior to CT Cycle 1. Subjects with prior or concomitant radiation therapy to areas other than the head and neck may be enrolled. Histologically confirmed diagnosis of breast or lung cancer (NSCLC or SCLC) Chemotherapy regimen containing AC ± T or EC ± T (for breast cancer), cisplatin or carboplatin (for NSCLC or SCLC), or doxorubicin (for SCLC) Subjects will receive the same regimen and dose of CT in the OM Treatment CT Cycle as was administered in the immediately preceding CT Cycle. Subjects will have had OM of WHO Grade of greater than or equal to 2 during CT Cycle 1 or Cycle 2 Subjects 18 years and older Karnofsky Performance Score >=60 Baseline laboratory assessments: Hemoglobin (Hgb) level >= 9 g/dL Absolute neutrophil count (ANC) >= 1.5 x 10 to the 9/L Platelet count >= 100 x 10 to the 9/L Serum bilirubin level <= 1.5 times institutional upper limit of normal (ULN) Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) level <= 2 times above ULN Females of childbearing potential must have a negative serum or urine pregnancy test result at the screening visit prior to the start of Cycle 1 and at the visit scheduled for <= 48 hours prior to the start of the OM Treatment CT Cycle Subjects with reproductive capability must agree to practice adequate contraception methods (males must use condoms or be surgically sterilized; females must be surgically sterilized, post-menopausal for at least 1 year, or use an appropriate double barrier method, prescribed birth control oral contraceptive, patch, implant, or injection during the course of the study and for up to 30 days after completion of study assessments) Absence of other serious concurrent medical illness Psychologically able to participate and comply with study requirements Exclusion Criteria: Prior history of oral mucositis with previous chemotherapy treatment Previous treatment with an anthracycline agent (other than low-dose neoadjuvant therapy) Active liver disease or serum AST and/or ALT level > 2 times above ULN Currently receiving an investigational agent, planning to receive an investigational agent during the study period, or received an investigational agent within 30 days of the first dose of SNX-1012 Use of an immunosuppressive regimen of systemic corticosteroids Unwilling/unable to receive periodic oral assessments by a study evaluator or unable to complete the daily self-reported outcome questionnaire Pregnant or breast-feeding women Bronchoalveolar carcinoma Metastases to the central nervous system Prior or planned focal radiation therapy in the head or neck regions for the treatment of cancer (prior radiation to areas other than the head and neck is permitted) Presence of active or history of chronic oral mucosal disease Presence or history of any other primary malignancy (curatively treated nonmelanoma skin cancer is allowed) History of chronic liver disease Active hepatitis A or B Unable to receive CT during the OM Treatment CT Cycle at the same regimen and/or dose as in the immediately preceding CT cycle. Known sensitivity to tetracyclines Known to be seropositive for HIV or HCV Use of an immunosuppressive regimen of systemic corticosteroids. Current alcohol dependence or drug abuse Psychological, social or familial or geographical reasons that would hinder or prevent study visits Compromised ability to give written informed consent and/or to comply with study procedures

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>SNX-1012 (meclocyline sulfosalicylate) tablets dissolved in water for oral swish and expectorate; 30 mg 4 times daily for 10 days | Drug: SNX-1012 (meclocycline sulfosalicylate)<br>* tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days<br>|
| Placebo Comparator: 2<br>placebo (matched to SNX-1012) tablets dissolved in water for oral swish and expectorate; 4 times daily for 10 days | Drug: placebo<br>* Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Duration of Ulcerative Oral Mucositis | All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to document the duration for those that developed recurrent ulcerative oral mucositis | At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants With Ulcerative Oral Mucositis | All randomized subjects were directly observed by trained evaluators for at least 10 consecutive days during the chemotherapy cycle to identify recurrence of ulcerative oral mucositis. | At least 10 consecutive days beginning on Day 1 of a chemotherapy cycle |